DK1913157T3 - EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling - Google Patents

EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling

Info

Publication number
DK1913157T3
DK1913157T3 DK06773201.6T DK06773201T DK1913157T3 DK 1913157 T3 DK1913157 T3 DK 1913157T3 DK 06773201 T DK06773201 T DK 06773201T DK 1913157 T3 DK1913157 T3 DK 1913157T3
Authority
DK
Denmark
Prior art keywords
egfr
patient response
inhibitor therapy
kras mutations
predicting patient
Prior art date
Application number
DK06773201.6T
Other languages
English (en)
Other versions
DK1913157T4 (da
Inventor
Kenneth J Hillan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36999856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1913157(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DK1913157T3 publication Critical patent/DK1913157T3/da
Application granted granted Critical
Publication of DK1913157T4 publication Critical patent/DK1913157T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK06773201.6T 2005-06-28 2006-06-13 EGFR- og KRAS-mutationer til forudsigelse af patientrespons på EGFR-hæmmerbehandling. DK1913157T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69517405P 2005-06-28 2005-06-28
PCT/US2006/023230 WO2007001868A1 (en) 2005-06-28 2006-06-13 Egfr and kras mutations

Publications (2)

Publication Number Publication Date
DK1913157T3 true DK1913157T3 (da) 2013-03-11
DK1913157T4 DK1913157T4 (da) 2017-01-23

Family

ID=36999856

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06773201.6T DK1913157T4 (da) 2005-06-28 2006-06-13 EGFR- og KRAS-mutationer til forudsigelse af patientrespons på EGFR-hæmmerbehandling.

Country Status (9)

Country Link
US (4) US20090202989A1 (da)
EP (1) EP1913157B2 (da)
JP (2) JP2008546421A (da)
CA (1) CA2612183C (da)
DK (1) DK1913157T4 (da)
ES (1) ES2398709T5 (da)
PL (1) PL1913157T5 (da)
SI (1) SI1913157T2 (da)
WO (1) WO2007001868A1 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
WO2005118876A2 (en) 2004-06-04 2005-12-15 Genentech, Inc. Egfr mutations
WO2006091899A2 (en) 2005-02-24 2006-08-31 Amgen Inc. Epidermal growth factor receptor mutations
WO2006107854A2 (en) 2005-04-01 2006-10-12 Amgen Inc. Epidermal growth factor receptor gene copy number
CA2612183C (en) * 2005-06-28 2015-08-11 Genentech, Inc. Egfr and kras mutations
US8129114B2 (en) * 2005-08-24 2012-03-06 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US7906342B2 (en) 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7858390B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
CA2680326A1 (en) † 2007-03-13 2008-09-18 Amgen Inc. K-ras mutations and anti-egfr antibody therapy
WO2008112274A2 (en) 2007-03-13 2008-09-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy
CN101795703B (zh) 2007-06-27 2015-05-06 里兰斯坦福初级大学理事会 肽酪氨酸酶抑制剂及其应用
CA2970108C (en) 2007-06-27 2020-04-07 The Board Of Trustees Of The Leland Stanford Junior University Oligopeptide tyrosinase inhibitors and uses thereof
SG10201609507TA (en) * 2008-02-01 2017-01-27 Gen Hospital Corp Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
NZ589143A (en) 2008-05-14 2012-02-24 Genomic Health Inc Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
GB2467691A (en) 2008-09-05 2010-08-11 Aueon Inc Methods for stratifying and annotating cancer drug treatment options
NZ592241A (en) * 2008-09-15 2012-11-30 Herlev Hospital Ykl-40 as a marker for gastrointestinal cancers
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
WO2010093465A1 (en) * 2009-02-11 2010-08-19 Caris Mpi, Inc. Molecular profiling of tumors
US20130143747A1 (en) * 2011-12-05 2013-06-06 Myriad Genetics, Incorporated Methods of detecting cancer
EP2470898A4 (en) * 2009-08-24 2013-03-13 Genentech Inc DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT IN DETECTION OF K-RAS MUTATIONS AND MEASURING RTK EXPRESSION LEVELS
EP2475390A4 (en) * 2009-09-09 2014-01-01 Quintiles Transnat Corp METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US20130029339A1 (en) * 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
JP5855568B2 (ja) * 2009-09-15 2016-02-09 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
EP2327793A1 (en) 2009-11-25 2011-06-01 Universität Zu Köln Pyrosequencing method for predicting the response of a patient towards anti cancer treatment
US20110207736A1 (en) * 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20130225424A1 (en) * 2010-03-03 2013-08-29 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
AU2011222867B2 (en) 2010-03-04 2014-03-06 Annika Algars Method for selecting patients for treatment with an EGFR inhibitor
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
CN102234683B (zh) * 2010-04-23 2013-07-17 广州益善生物技术有限公司 一种egfr基因突变检测液相芯片
JP2013531987A (ja) * 2010-06-14 2013-08-15 キアゲン ゲーエムベーハー 固定生物学的試料から生体分子を抽出するためのターゲット細胞または組織を決定するための方法
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2012040387A1 (en) 2010-09-24 2012-03-29 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
JP5996431B2 (ja) * 2010-09-30 2016-09-21 Ｌｓｉｐファンド運営合同会社 優性変異遺伝子発現抑制剤
JP6219721B2 (ja) 2010-11-10 2017-10-25 エキソソーム ダイアグノスティックス インコーポレイテッド 核酸含有粒子の単離および該粒子からの核酸の抽出のための方法
GB2506760B (en) * 2011-01-14 2015-07-22 Genefirst Ltd Allele specific primers for EGFR exon 21 specific mutations
US8914238B2 (en) 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2012162613A2 (en) * 2011-05-26 2012-11-29 Brandeis University Detection of sequence variants in the human epidermal growth factor receptor (egfr) gene
US9127318B2 (en) * 2011-10-18 2015-09-08 Exact Sciences Corporation Multiplexed KRAS mutation detection assay
EP2776043B1 (en) 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013134786A2 (en) * 2012-03-09 2013-09-12 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
ES2668861T3 (es) * 2012-07-31 2018-05-22 Crown Bioscience, Inc. (Taicang) Marcadores histológicos para identificar pacientes con carcinoma de pulmón de células no pequeñas para el tratamiento con un fármaco anti EGFR
EP2884979B1 (en) 2012-08-17 2019-06-26 F.Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
WO2014052613A2 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
WO2015154005A1 (en) 2014-04-04 2015-10-08 Amgen Inc. Biomarkers and use of met inhibitor for treatment of cancer
US10525524B2 (en) 2014-07-09 2020-01-07 The Boeing Company Dual-interface coupler
CN106834484A (zh) * 2017-02-27 2017-06-13 宁夏海诚电化信息科技有限公司 一种直肠癌体外检测方法
BR112022003165A2 (pt) * 2019-08-22 2022-05-17 Univ Michigan Regents Método de tratamento de cânceres associados a kras

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683203A (en) * 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5981725A (en) * 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5869245A (en) 1996-06-05 1999-02-09 Fox Chase Cancer Center Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands
EP1163365A4 (en) * 1999-02-25 2002-11-20 Auckland Uniservices Ltd DIAGNOSIS AND THERAPY OF EARLY OVARY FAILURE
EP1170011A1 (en) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Novel use of inhibitors of the epidermal growth factor receptor
US20050164218A1 (en) * 2003-05-30 2005-07-28 David Agus Gene expression markers for response to EGFR inhibitor drugs
CN104774931B (zh) * 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
WO2005118876A2 (en) * 2004-06-04 2005-12-15 Genentech, Inc. Egfr mutations
CA2612183C (en) * 2005-06-28 2015-08-11 Genentech, Inc. Egfr and kras mutations

Also Published As

Publication number Publication date
WO2007001868A1 (en) 2007-01-04
EP1913157B1 (en) 2012-11-28
EP1913157A1 (en) 2008-04-23
JP5827935B2 (ja) 2015-12-02
EP1913157B2 (en) 2016-10-26
CA2612183C (en) 2015-08-11
DK1913157T4 (da) 2017-01-23
PL1913157T5 (pl) 2017-09-29
ES2398709T3 (es) 2013-03-21
PL1913157T3 (da) 2013-04-30
US20150197814A1 (en) 2015-07-16
US20110081651A1 (en) 2011-04-07
CA2612183A1 (en) 2007-01-04
ES2398709T5 (es) 2017-04-18
JP2013099330A (ja) 2013-05-23
SI1913157T1 (sl) 2013-02-28
US20090202989A1 (en) 2009-08-13
US20130203788A1 (en) 2013-08-08
JP2008546421A (ja) 2008-12-25
SI1913157T2 (sl) 2017-02-28

Similar Documents

Publication Publication Date Title
DK1913157T3 (da) EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling
LTC1761540I2 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
NO20085030L (no) Pyrrolopyrimidinforbindelser og deres anvendelser
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK2099796T3 (da) Aza-indolyl-forbindelser og fremgangsmåder for anvendelse
DK1871738T3 (da) N-alkylcarbonylaminosyreester- og N-alkylcarbonylaminolactonforbindelser og deres anvendelse
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1962895T3 (da) TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
CY2014012I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK1928457T3 (da) Quinoliner og deres terapeutiske anvendelse
DK1924577T3 (da) Substituerede benzimidazoler og fremgangsmåder til fremstilling
DK2152748T3 (da) Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
DK1954140T3 (da) Glycerollevulinatketaler og deres anvendelse
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
DE502005007353D1 (de) Zervikale zwischenwirbelprothese
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
NO20055211D0 (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
NO20054709L (no) Sammenfoyningssystem og anvendelse av dette
DE602005022115D1 (de) Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft